Clinical Trials Logo

Filter by:
NCT ID: NCT02355652 Withdrawn - Clinical trials for Total Knee Arthroplasty

Cemented Versus Uncemented Total Knee Arthroplasty : a Prospective Randomized Study

HLS
Start date: January 2015
Phase: Phase 4
Study type: Interventional

The goal of this prospective randomized double-blind study is to compare clinical and radiological results of cemented and uncemented total knee arthroplasty (TKA). Two hundred and fifty patients will be randomized in two groups : cemented TKA and uncemented TKA. The primary outcome is the comparison of the International Knee Society (IKS) Score revised in 2011 at one year postoperative. The second outcome is the comparison of standard one year-postoperative x-rays looking for signs of loosening.

NCT ID: NCT02338531 Withdrawn - Breast Cancer Clinical Trials

Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer

RHEA
Start date: June 2015
Phase: Phase 2
Study type: Interventional

This is a phase II open label Biomarker Research Study off PF-03084014 in non-metastatic triple-negative breast cancer patients with residual disease (cHEmoresistant) after completion of standard neoadjuvant chemotherapy.

NCT ID: NCT02333903 Withdrawn - Obesity Clinical Trials

Adapted Physical Activity Program After Sleeve Gastrectomy

PEEPSO
Start date: January 2015
Phase: N/A
Study type: Interventional

This study compares the ratio of lean mass losses over total body mass losses between patients undergoing sleeve gastrectomy followed by physical activity training versus patients undergoing sleeve gastrectomy only

NCT ID: NCT02328742 Withdrawn - Infertility Clinical Trials

Development of a Bioabsorbable Medical Device for the Prevention of Postoperative Intra-uterine Adhesions.

PréSynUT-1
Start date: November 2015
Phase: N/A
Study type: Observational

The main objective of this study is to describe the level of expression of the biological factors involved in the formation of adhesions (Transforming growth factor beta, Activin A, inhibin) at the time of a first diagnostic hysteroscopy among women with synechia, another intracavitary disease or no intracavitary disease.

NCT ID: NCT02323516 Withdrawn - Cancer Clinical Trials

Evaluation of the Efficacy of Low-dose Acetylsalicylic Acid on Diarrhea Induced by Anti-cancer Targeted Therapies.

ASPIDIA
Start date: December 2014
Phase: Phase 2
Study type: Interventional

The mechanisms of action of the side effects associated with targeted therapies are still poorly understood. He was found in patients treated with gefitinib, increased levels of thromboxane B2 and P-selectin Thromboxane B2 is the result of the hydrolysis of thromboxane A2, which is itself obtained from Prostaglandin H2 under the action of the thromboxane synthetase. The thromboxane A2 is produced by platelets and the active pro-thrombotic properties as follows: stimulation of platelets and activation of other increased platelet aggregation. The selectins are cell adhesion proteins with a role in the adhesion phenomena. P-selectin is expressed by platelets and endothelial cells. The demonstration of increased plasma levels of thromboxane B2 and P-selectin leaves suggest a role of platelet activation in the occurrence of side effects associated with targeted therapies. Kanazawa's study was conducted in 39 Japanese patients, trying to assess the value of low-dose acetylsalicylic acid or 100mg per day, that is to say, anti-aggrégantes doses, the occurrence rash and diarrhea induced by gefitinib. In this study, the group of patients treated with acetylsalicylic acid presented a lower rate of side effects significantly, 58.3% versus 77.8%. The frequency of diarrhea was 18.5% (or 5 patients) in the standard group versus 0% in the group with acetylsalicylic acid. Similarly, it was found a reduction in the occurrence of skin rash, 33.3% or 4 patients in the acetylsalicylic acid group versus 74.1% s, 20 patients in the standard group. Finally, in this study, it was not revealed significant differences in terms of response to treatment with gefitinib (37% in the standard group versus 33% in the group treated with aspirin patient) It does not exist in our knowledge of prospective data evaluating the effect of acetylsalicylic acid on the reduction of side effects associated with targeted in a population of patients of Caucasian-type treatment.

NCT ID: NCT02313350 Withdrawn - Sciatica Clinical Trials

Intradiscal Discogel® in Resistant Sciatica

EDIS
Start date: September 2017
Phase: N/A
Study type: Interventional

Sciatica due to herniated disc is a major cause of disability in young adults. Surgery is the gold-standard and the only controlled treatment in case of failure of conservative treatment. Percutaneous chemonucleolysis with Discogel® may be a valuable alternative to surgery. In addition, Discogel® chemonucleolysis appears as a relatively innocuous technique which may avoid 2% complications after disc surgery and 5% repeated surgery (according to recent trials). This will be the first randomized trial comparing Discogel® chemonucleolysis versus surgery in patients with sciatica due to lumbar disc herniation and unresponsive to conservative medical treatments (including epidural steroid injections) Our expectation is that Discogel® chemonucleolysis will avoid surgery in 80% of the patients.

NCT ID: NCT02309450 Withdrawn - Clinical trials for Hepatitis C Virus Genotype 4 Infection

Pilot Study to Assess Efficacy and Safety of a Triple Therapy With Asunaprevir, Daclatasvir, and BMS-791325 in HCV Genotype 4-infected Patients After Failure of Pegylated Interferon-Ribavirin Regimen

QUATTROTURBO
Start date: December 2014
Phase: Phase 2
Study type: Interventional

ANRS HC 33 is a pilot study to assess efficacy and safety of a DCV 3DAA therapy with Asunaprevir, Daclatasvir and BMS-791325 in HCV genotype 4-infected patients after failure of pegylated Interferon-Ribavirin regimen. Proportion of patients with cirrhosis will be limited to 50% of all patients included, cirrhosis being defined as a METAVIR score of F4 on the liver biopsy or an hepatic impulse elastometry ≥ 14 kPa or a Fibrotest® result > 0,75.

NCT ID: NCT02307604 Withdrawn - Brain Neoplasms Clinical Trials

SPECTAbrain: Screening Patients With Brain Tumors for Efficient Clinical Trial Access

SPECTAbrain
Start date: May 2016
Phase:
Study type: Observational [Patient Registry]

The SPECTAbrain protocol describes a structure for screening patients with brain tumors to efficiently allocate eligible patients in relevant therapeutic biomarker-driven clinical trials. Efficiency is promoted through the creation of a clinical database of brain tumor patients and the respective human biological material biobank for molecular characterization. The main objectives are to: - Allocate patients to clinical trials according to the clinical characteristics and molecular profile of their tumor; - Identify or validate new molecularly defined subgroups of tumors; - Investigate the prevalence of novel biomarkers to plan future clinical trials; - Enable exploratory/future research; - Facilitate establishment of quality-assured and validated tests for Central Nervous System (CNS) tumor biomarkers;

NCT ID: NCT02282176 Withdrawn - Clinical trials for Bronchopulmonary Dysplasia

TINN2: Treat Infection in NeoNates 2

TINN2
Start date: January 2015
Phase: Phase 3
Study type: Interventional

The aim of the TINN2 study is to evaluate the efficacy of azithromycin in prevention of bronchopulmonary dysplasia in preterm neonates.

NCT ID: NCT02253017 Withdrawn - Cataract Clinical Trials

Evaluation of Therapeutic Strategies in Pediatric Cataract Surgery

EP3C
Start date: September 2014
Phase:
Study type: Observational

The purpose of this observational study is to assess the therapeutic strategies in the treatment of pediatric cataracts.